Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹3,653 Cr
up ₹156 Cr vs Jul 2020
- Stocks held
- 20
- unchanged
- Top 10 weight
- 77.9%
- of the portfolio in its ten largest
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In August 2020 it disclosed 20 stocks worth ₹3,653 Cr, up ₹156 Cr from Jul 2020. Its largest positions were Divi's Laboratories Limited (10.3%), Sun Pharmaceutical Industries Limited (10.3%), Lupin Limited (10.2%); the ten largest together made up 77.9% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 78.7% of its equity. Cash and debt stood at 3.4%. Compared with Jul 2020 the fund entered 1 new stock and exited 1.
Against 226 other Sectoral / Thematic funds
Concentration
98%
Top-10 weight is higher than 98% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
52%
Holds more cash than 52% of peers
What these mean: concentration · cash
Holdings in August 2020
Download CSVEvery line the fund disclosed, with the change against Jul 2020. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Divi's Laboratories Limited | 10.26% | up 1.28 pts | ₹375 Cr | up ₹60.8 Cr | Added |
| Sun Pharmaceutical Industries Limited | 10.26% | up 0.67 pts | ₹375 Cr | up ₹39.6 Cr | Added |
| Lupin Limited | 10.16% | up 1.41 pts | ₹371 Cr | up ₹65.3 Cr | Added |
| Aurobindo Pharma Limited | 9.52% | down 0.23 pts | ₹348 Cr | up ₹6.7 Cr | Added |
| Dr. Reddy's Laboratories Limited | 9.46% | down 0.69 pts | ₹345 Cr | down ₹9.5 Cr | Trimmed |
| Cipla Limited | 9.18% | down 0.09 pts | ₹335 Cr | up ₹11.3 Cr | Added |
| Thyrocare Technologies Limited | 5.81% | up 0.67 pts | ₹212 Cr | up ₹32.7 Cr | Added |
| Fortis Healthcare Limited | 5.24% | down 0.45 pts | ₹191 Cr | down ₹7.5 Cr | Trimmed |
| Zydus Lifesciences Limited | 4.06% | up 0.19 pts | ₹148 Cr | up ₹12.8 Cr | Added |
| Sanofi India Limited | 3.94% | up 0.05 pts | ₹144 Cr | up ₹7.9 Cr | Added |
| Syngene International Limited | 3.90% | down 0.98 pts | ₹142 Cr | down ₹28.3 Cr | Trimmed |
| Abbott India Limited | 3.59% | up 0.48 pts | ₹131 Cr | up ₹22.3 Cr | Added |
| Cash, TREPS & receivables | 3.41% | down 1.12 pts | ₹125 Cr | down ₹33.9 Cr | Trimmed |
| Narayana Hrudayalaya Limited | 3.25% | up 0.53 pts | ₹119 Cr | up ₹23.7 Cr | Added |
| Biocon Limited | 2.58% | down 0.35 pts | ₹94.2 Cr | down ₹8.4 Cr | Trimmed |
| Indoco Remedies Limited | 2.04% | down 0.07 pts | ₹74.4 Cr | up ₹81 L | Added |
| Laurus Labs Limited | 1.24% | down 0.09 pts | ₹45.3 Cr | down ₹1.3 Cr | Trimmed |
| Alkem Laboratories Limited | 0.82% | down 1.55 pts | ₹29.8 Cr | down ₹53 Cr | Trimmed |
| Pfizer Limited | 0.62% | up 0.62 pts | ₹22.6 Cr | up ₹22.6 Cr | New |
| Healthcare Global Enterprises Limited | 0.35% | down 0.03 pts | ₹12.7 Cr | down ₹49 L | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 0.32% | up 0.26 pts | ₹11.8 Cr | up ₹9.6 Cr | Added |
What changed, Jul 2020 to Aug 2020
New New positions (1)
- Pfizer Limited0.6% · ₹22.6 Cr
Exited Exited (1)
- Torrent Pharmaceuticals Limitedwas 0.5% · ₹17.4 Cr
Added Biggest additions
- Lupin Limitedup ₹65.3 Cr (+1.41% pts)
- Divi's Laboratories Limitedup ₹60.8 Cr (+1.28% pts)
- Sun Pharmaceutical Industries Limitedup ₹39.6 Cr (+0.67% pts)
- Thyrocare Technologies Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jul 2020, the weight rose most in Pharmaceuticals & Biotechnology (+0.6 pts), and fell most in Healthcare Services (−0.5 pts).
- Pharmaceuticals & Biotechnology78.1% → 78.7%+0.6 pts
- Healthcare Services19.7% → 19.2%−0.5 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Feb 2020 | May 2020 | Jul 2020 | Aug 2020 |
|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 77.2% | 80.3% | 78.1% | 78.7% |
| Healthcare Services | 20.8% | 17.4% | 19.7% | 19.2% |
| Pharmaceuticals | 2.1% | 2.3% | 2.2% | 2.1% |
Allocation in Aug 2020change vs Jul 2020
- Pharmaceuticals & Biotechnology (14)78.7%▲ 0.6 pts
- Healthcare Services (5)19.2%▼ 0.5 pts
- Pharmaceuticals (1)2.1%▼ 0.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Aug 2020
3.4%
▼ 1.1 pts vs Jul 2020
- Cash alone
- 3.4%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- −<0.1% – 4.5%
- lowest to highest · record 4.5% in Jul 2020
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.